Leucine‐rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes

Mutations in leucine‐rich repeat kinase 2 (LRRK2) gene have been pathogenically linked to Parkinson's disease, and pharmacological inhibition of LRRK2 is being pursued to tackle nigro‐striatal dopaminergic neurodegeneration. However, LRRK2 kinase inhibitors may have manifold actions, affecting...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercatelli, Daniela, Bolognesi, Paolo, Frassineti, Martina, Pisanò, Clarissa A., Longo, Francesco, Shimshek, Derya R., Morari, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536420/
https://www.ncbi.nlm.nih.gov/pubmed/31149340
http://dx.doi.org/10.1002/prp2.484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536420/
https://www.ncbi.nlm.nih.gov/pubmed/31149340
http://dx.doi.org/10.1002/prp2.484

Ejemplares similares